50.50
price up icon0.64%   0.32
 
loading
전일 마감가:
$50.18
열려 있는:
$50.29
하루 거래량:
956.93K
Relative Volume:
0.45
시가총액:
$6.07B
수익:
$692.26M
순이익/손실:
$-512.41M
주가수익비율:
-11.91
EPS:
-4.24
순현금흐름:
$-274.36M
1주 성능:
+0.94%
1개월 성능:
+10.29%
6개월 성능:
+49.59%
1년 성능:
+77.75%
1일 변동 폭
Value
$49.25
$50.91
1주일 범위
Value
$49.25
$53.42
52주 변동 폭
Value
$20.14
$53.42

가든트헬스 Stock (GH) Company Profile

Name
명칭
Guardant Health Inc
Name
전화
855-698-8887
Name
주소
3100 HANOVER STREET, PALO ALTO
Name
직원
2,021
Name
트위터
@guardanthealth
Name
다음 수익 날짜
2024-11-06
Name
최신 SEC 제출 서류
Name
GH's Discussions on Twitter

GH을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Diagnostics & Research icon
GH
Guardant Health Inc
50.50 6.07B 692.26M -512.41M -274.36M -4.24
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
429.33 156.49B 42.90B 6.52B 6.72B 17.05
Diagnostics & Research icon
DHR
Danaher Corp
203.20 145.01B 23.82B 3.77B 4.90B 5.15
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
547.01 42.30B 3.93B 894.97M 837.70M 10.82
Diagnostics & Research icon
A
Agilent Technologies Inc
121.38 34.24B 6.63B 1.17B 1.19B 4.05
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
164.24 27.64B 15.50B 1.33B 2.16B 7.34

가든트헬스 Stock (GH) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-04-10 개시 Mizuho Outperform
2025-01-23 개시 Barclays Overweight
2024-06-28 업그레이드 Guggenheim Neutral → Buy
2024-06-03 재개 Jefferies Buy
2024-04-24 재개 Craig Hallum Buy
2023-12-14 개시 Guggenheim Neutral
2023-12-13 개시 Wolfe Research Peer Perform
2023-11-13 업그레이드 Raymond James Mkt Perform → Outperform
2023-09-28 개시 Bernstein Outperform
2023-09-27 업그레이드 Piper Sandler Neutral → Overweight
2023-07-05 재개 JP Morgan Overweight
2023-05-26 업그레이드 Citigroup Neutral → Buy
2023-05-05 개시 UBS Buy
2023-03-09 다운그레이드 Citigroup Buy → Neutral
2023-01-05 개시 Scotiabank Sector Outperform
2022-11-01 다운그레이드 Piper Sandler Overweight → Neutral
2022-10-19 개시 Craig Hallum Buy
2022-10-06 개시 Stephens Overweight
2022-08-25 개시 Credit Suisse Outperform
2022-06-03 개시 Piper Sandler Overweight
2022-04-28 재개 BTIG Research Buy
2022-02-24 재확인 Canaccord Genuity Buy
2022-02-24 재확인 Citigroup Buy
2022-02-24 재확인 Cowen Outperform
2022-02-24 재확인 Morgan Stanley Overweight
2022-02-24 재확인 SVB Leerink Outperform
2022-02-24 재확인 Stifel Buy
2022-02-24 재확인 Wells Fargo Overweight
2021-10-15 재개 Cowen Outperform
2021-06-15 개시 Raymond James Mkt Perform
2021-06-03 개시 Goldman Buy
2021-05-25 개시 Wells Fargo Overweight
2021-01-11 개시 Stifel Buy
2020-09-09 개시 Morgan Stanley Overweight
2020-06-12 개시 BTIG Research Buy
2020-02-21 개시 Guggenheim Buy
2020-01-07 개시 Citigroup Buy
2019-08-07 재확인 Canaccord Genuity Buy
2019-04-16 개시 Canaccord Genuity Buy
2019-04-10 업그레이드 BofA/Merrill Neutral → Buy
2019-02-28 재확인 BofA/Merrill Neutral
2018-10-29 개시 BofA/Merrill Neutral
2018-10-29 개시 JP Morgan Overweight
2018-10-29 개시 William Blair Outperform
모두보기

가든트헬스 주식(GH)의 최신 뉴스

pulisher
Jun 18, 2025

Guardant Health’s Multi-Cancer Detection Test Wins FDA Breakthrough Designation - Medical Product Outsourcing

Jun 18, 2025
pulisher
Jun 17, 2025

Australian biotech uncovers broader view of tumour genetics with liquid biopsy - Mugglehead Magazine

Jun 17, 2025
pulisher
Jun 16, 2025

Insider Sell: Meghan Joyce Sells Shares of Guardant Health Inc (GH) - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Guardant Health director sells shares worth $157,573 - Investing.com

Jun 16, 2025
pulisher
Jun 16, 2025

Guardant Health Executives Sell Shares - TradingView

Jun 16, 2025
pulisher
Jun 16, 2025

Guardant Health up 4% on Q1 beats, 2025 guidance revenue raise - MSN

Jun 16, 2025
pulisher
Jun 16, 2025

Non-Invasive Cancer Testing Market Forecast | Major Players: Guardant Health, Exact Sciences, Qiagen, Natera Inc. - openPR.com

Jun 16, 2025
pulisher
Jun 16, 2025

Guardant Health (NASDAQ:GH) Given New $65.00 Price Target at Mizuho - MarketBeat

Jun 16, 2025
pulisher
Jun 14, 2025

(GH) Investment Report - news.stocktradersdaily.com

Jun 14, 2025
pulisher
Jun 13, 2025

Mizuho raises Guardant Health price target on positive Shield test outlook - Investing.com Canada

Jun 13, 2025
pulisher
Jun 13, 2025

Guardant Health (GH) Price Target Raised to $65 by Mizuho | GH S - GuruFocus

Jun 13, 2025
pulisher
Jun 12, 2025

Molecular Diagnostics for Cancer Market Research 2025: Advances in Personalized Medicine and Liquid Biopsies Reshape Industry Landscape - GlobeNewswire Inc.

Jun 12, 2025
pulisher
Jun 12, 2025

Guardant Health, Inc. (NASDAQ:GH) Receives $53.29 Consensus PT from Analysts - MarketBeat

Jun 12, 2025
pulisher
Jun 10, 2025

Guardant Health Wins Fast Company's 2025 World Changing Ideas Aw - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening | GH Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Guardant Health Wins Fast Company’s 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening - Yahoo Finance

Jun 10, 2025
pulisher
Jun 10, 2025

Circulating Tumor DNA–Guided Risk Stratification in Colorectal Cancer: Evolving Evidence and Future Utility - The ASCO Post

Jun 10, 2025
pulisher
Jun 10, 2025

Insider Sell: Amirali Talasaz Sells 119,284 Shares of Guardant H - GuruFocus

Jun 10, 2025
pulisher
Jun 09, 2025

Guardant Health Inc (GH) Shares Up 4.04% on Jun 9 - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Guardant Health at Goldman Sachs Conference: Strategic Growth Insights By Investing.com - Investing.com Canada

Jun 09, 2025
pulisher
Jun 09, 2025

Transcript : Guardant Health, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10 - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer - BioSpace

Jun 09, 2025
pulisher
Jun 09, 2025

New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer | GH Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 07, 2025

ARK Investment Acquires 99.6K Shares of Guardant Health (GH) | G - GuruFocus

Jun 07, 2025
pulisher
Jun 06, 2025

Guardant Health, Inc. (GH)’s ctDNA Test Predicts Colon Cancer Recurrence Risk in Stage III Patients - MSN

Jun 06, 2025
pulisher
Jun 06, 2025

Insider Sell: Kumud Kalia Sells 4,000 Shares of Guardant Health Inc (GH) - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Guardant Health Inc (GH) Shares Up 3.5% on Jun 5 - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Mackenzie Financial Corp Has $230,000 Holdings in Guardant Health, Inc. (NASDAQ:GH) - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Guardant Health Shares Climb on FDA Breakthrough Status for Cancer Detection Test - MSN

Jun 06, 2025
pulisher
Jun 05, 2025

Minimal Residual Disease Testing Market Set to Witness - openPR.com

Jun 05, 2025
pulisher
Jun 05, 2025

Colorectal Cancer Diagnostics Market Size To Boom with Top Key - openPR.com

Jun 05, 2025
pulisher
Jun 04, 2025

ARK Investment Acquires 99.6K Shares of Guardant Health (GH) | GH Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Cathie Wood’s ARK sells Palantir and Roblox, buys Veracyte and Guardant - Investing.com Australia

Jun 04, 2025
pulisher
Jun 04, 2025

Cathie Wood’s ARK sells Palantir and Roblox, buys Veracyte and Guardant By Investing.com - Investing.com UK

Jun 04, 2025
pulisher
Jun 04, 2025

Guardant Health, Inc. (GH) Expands Liquid Biopsy to Pinpoint Tumor Origins and Biomarkers - MSN

Jun 04, 2025
pulisher
Jun 04, 2025

Guardant Health gets FDA breakthrough device status for cancer detection test - MSN

Jun 04, 2025
pulisher
Jun 04, 2025

Guardant Health’s MCD test earns FDA breakthrough designation - Yahoo

Jun 04, 2025
pulisher
Jun 04, 2025

111 Capital Purchases Shares of 8,303 Guardant Health, Inc. (NASDAQ:GH) - MarketBeat

Jun 04, 2025
pulisher
Jun 04, 2025

Guardant Health’s cancer test earns FDA breakthrough status By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 03, 2025

Leerink Partners maintains outperform rating for Guardant Health stock By Investing.com - Investing.com Canada

Jun 03, 2025
pulisher
Jun 03, 2025

ARK Investment Acquires 173K Shares of Guardant Health (GH) | GH Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Guardant Health (GH) Stock Surges on FDA Breakthrough Designatio - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Why Guardant Health Stock Surged Nearly 9% Higher Today - MSN

Jun 03, 2025
pulisher
Jun 03, 2025

NCCN Adds 2 Tests to CRC Screening Guidelines - OncLive

Jun 03, 2025
pulisher
Jun 03, 2025

Why Is Cancer Diagnostic Guardant Health Stock Trading Higher On Tuesday?Guardant Health (NASDAQ:GH) - Benzinga

Jun 03, 2025
pulisher
Jun 03, 2025

Guardant Health shares rise following FDA breakthrough designation By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 03, 2025

Guardant Health shares rise following FDA breakthrough designation - Investing.com

Jun 03, 2025
pulisher
Jun 03, 2025

Guardant Health (GH) Gains as FDA Grants Breakthrough Designatio - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Guardant Health's Shield Multi-Cancer Test Receives FDA Breakthrough Device Designation - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

Guardant Health’s cancer test earns FDA breakthrough status - Investing.com

Jun 03, 2025
pulisher
Jun 03, 2025

Guardant Health (GH) Receives FDA Breakthrough Designation for Cancer Detection Test | GH Stock News - GuruFocus

Jun 03, 2025

가든트헬스 (GH) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

가든트헬스 주식 (GH) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Kalia Kumud
Chief Information Officer
Jul 01 '25
Option Exercise
0.00
2,691
0
21,865
Freeman Chris
Chief Commercial Officer
Jul 01 '25
Option Exercise
0.00
3,596
0
50,353
EAGLE CRAIG
Chief Medical Officer
Jul 01 '25
Option Exercise
0.00
3,381
0
38,505
Chudova Darya
Chief Technology Officer
Jul 01 '25
Option Exercise
0.00
3,007
0
82,819
Bell Michael Brian
Chief Financial Officer
Jul 01 '25
Option Exercise
0.00
2,084
0
44,085
Talasaz AmirAli
Co-Chief Executive Officer
Jun 30 '25
Option Exercise
0.00
4,815
0
2,074,271
Talasaz AmirAli
Co-Chief Executive Officer
Jul 01 '25
Option Exercise
0.00
23,997
0
1,995,827
Talasaz AmirAli
Co-Chief Executive Officer
Jul 01 '25
Sale
50.88
100,000
5,087,630
1,971,830
Krognes Steve E.
Director
Jun 30 '25
Option Exercise
0.00
154
0
17,819
Eltoukhy Helmy
Co-Chief Executive Officer
Jun 30 '25
Option Exercise
0.00
4,815
0
2,414,105
diagnostics_research DGX
$176.92
price up icon 0.18%
diagnostics_research WAT
$350.22
price down icon 0.48%
diagnostics_research LH
$261.89
price up icon 0.73%
$161.76
price up icon 0.12%
diagnostics_research MTD
$1,209.08
price up icon 0.28%
diagnostics_research IQV
$164.24
price down icon 0.25%
자본화:     |  볼륨(24시간):